Recruiting INTERVENTIONAL NCT06869551

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis

Sponsor: Bristol-Myers Squibb

Conditions Juvenile Psoriatic Arthritis

Interventions Deucravacitinib Placebo

Updated 11 times since 2025 Last updated: Apr 13, 2026 Started: Mar 13, 2025 Primary completion: Mar 6, 2030 Completion: Mar 4, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Juvenile Psoriatic Arthritis, this trial is actively recruiting participants. The trial is conducted by Bristol-Myers Squibb and has accumulated 11 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Apr 16, 2026 — Present [daily]

Recruiting

Phase: PHASE3 → None
Mar 2026 — Apr 2026 [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3

▶ Show 6 earlier versions

Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3

First recorded

Mar 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Austin, United States , Barcelona, Spain , Beijing, China , Beijing, China , Belo Horizonte, Brazil , Changchun, China , Chicago, United States , Chongqing, China and 37 more locations